Home › Trial NCT05654623
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Trial IDNCT05654623
- StatusActive Not Recruiting
- PhasePhase 3
- Study typeInterventional
- SponsorPfizer
- Enrollment624
- Start date2023-03-03
- ConditionsAdvanced Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.